A Phase 1, Open-label, Dose-escalation Study of SNX 5422 and Erlotinib in Subjects With Lung Adenocarcinoma With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Trial Profile

A Phase 1, Open-label, Dose-escalation Study of SNX 5422 and Erlotinib in Subjects With Lung Adenocarcinoma With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Aug 2016

At a glance

  • Drugs SNX 5422 (Primary) ; Erlotinib
  • Indications Lung cancer
  • Focus Adverse reactions
  • Sponsors Esanex
  • Most Recent Events

    • 15 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 23 May 2016 Planned End Date changed from 1 May 2016 to 1 Aug 2016.
    • 19 Nov 2015 Planned End Date changed from 1 Feb 2016 to 1 May 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top